The US Department of Health and Human Services proposes reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act. This shift recognises medical benefits and lower abuse potential but faces delays due to potential legal battles. Future DEA decisions and industry mobilization will determine the effective date. Financial implications, including tax burdens and company valuations, are significant.
Read the full story here
Written by: Adam Jackson
Published on February 1, 2024 at 10:44PM
Source: Green Market Report (opens in new tab)